Cantor Fitzgerald Reaffirms “Neutral” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Cantor Fitzgerald reiterated their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPTFree Report) in a research report report published on Friday morning, Benzinga reports. They currently have a $128.00 price objective on the biotechnology company’s stock.

Other equities analysts have also issued research reports about the stock. Oppenheimer upgraded shares of Sarepta Therapeutics from a market perform rating to an outperform rating and set a $180.00 price objective on the stock in a report on Tuesday, May 14th. Robert W. Baird boosted their price objective on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an outperform rating in a report on Friday. BMO Capital Markets reiterated an outperform rating and issued a $170.00 price objective on shares of Sarepta Therapeutics in a report on Friday, June 14th. JPMorgan Chase & Co. decreased their price objective on shares of Sarepta Therapeutics from $177.00 to $175.00 and set an overweight rating for the company in a report on Friday, May 3rd. Finally, Mizuho increased their price objective on shares of Sarepta Therapeutics from $145.00 to $179.00 and gave the company a buy rating in a report on Friday, May 17th. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $177.65.

Read Our Latest Analysis on Sarepta Therapeutics

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $160.72 on Friday. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $15.19 billion, a price-to-earnings ratio of 1,461.09 and a beta of 0.96. The firm’s fifty day simple moving average is $125.56 and its 200 day simple moving average is $120.18. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.84. The business had revenue of $413.50 million for the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The business’s quarterly revenue was up 63.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.44) EPS. As a group, equities research analysts expect that Sarepta Therapeutics will post 2.99 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Dallan Murray sold 3,635 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the transaction, the insider now owns 18,125 shares of the company’s stock, valued at approximately $2,537,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Capital Fund Management S.A. acquired a new position in Sarepta Therapeutics in the 4th quarter worth approximately $7,299,000. Vanguard Group Inc. boosted its stake in Sarepta Therapeutics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company’s stock worth $1,039,212,000 after purchasing an additional 41,465 shares during the period. ADAR1 Capital Management LLC purchased a new stake in Sarepta Therapeutics in the 4th quarter worth approximately $777,000. Principal Financial Group Inc. lifted its position in Sarepta Therapeutics by 125.3% in the 4th quarter. Principal Financial Group Inc. now owns 49,539 shares of the biotechnology company’s stock worth $4,777,000 after buying an additional 27,549 shares in the last quarter. Finally, Great Point Partners LLC lifted its position in Sarepta Therapeutics by 14.0% in the 4th quarter. Great Point Partners LLC now owns 80,000 shares of the biotechnology company’s stock worth $7,714,000 after buying an additional 9,800 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

(Get Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

See Also

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.